Akero Therapeutics Acquired by Novo Nordisk for $5.2B

The latest announcement is out from Akero Therapeutics ( (AKRO) ).

On October 9, 2025, Akero Therapeutics announced its acquisition by Novo Nordisk for up to $5.2 billion. The merger agreement stipulates that Akero shareholders will receive $54 per share in cash and a contingent value right (CVR) of $6 per share, contingent upon regulatory approval of efruxifermin for MASH treatment by June 30, 2031. This acquisition is expected to enhance Novo Nordisk’s capabilities in metabolic treatments and accelerate the development and commercialization of EFX, benefiting patients globally. The transaction, approved by Akero’s Board, is anticipated to close by year-end, pending shareholder and regulatory approvals.

The most recent analyst rating on (AKRO) stock is a Hold with a $54.00 price target. To see the full list of analyst forecasts on Akero Therapeutics stock, see the AKRO Stock Forecast page.

Spark’s Take on AKRO Stock

According to Spark, TipRanks’ AI Analyst, AKRO is a Neutral.

Akero’s stock score reflects strong technical momentum and positive corporate developments, which are key drivers. However, financial challenges with no current revenue and operational losses weigh down the overall score. The promising clinical trial results provide a potential catalyst for future growth.

To see Spark’s full report on AKRO stock, click here.

More about Akero Therapeutics

Akero Therapeutics is a clinical-stage company focused on developing transformational treatments for serious metabolic diseases with high unmet medical needs, such as metabolic dysfunction-associated steatohepatitis (MASH). Their lead product candidate, efruxifermin (EFX), is under evaluation in Phase 3 clinical studies, aiming to address various stages of MASH.

Average Trading Volume: 1,052,734

Technical Sentiment Signal: Buy

Current Market Cap: $3.68B

For a thorough assessment of AKRO stock, go to TipRanks’ Stock Analysis page.